Sanara MedTech Inc. (SMTI)
Nasdaq · Healthcare · Medical Instruments & Supplies
$35.00+0.43%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $322M
- Forward P/E
- 64.8
- 52-week range
- $16.05 – $35.34
- 52-week change
- +11.48%
- EPS (trailing)
- −$0.04
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $103M (+18.98%)
- Net income
- $37.6M
- Operating margin
- 7.1%
- Diluted EPS
- −$4.36
- Free cash flow
- $2.2M
From the company’s annual report on SEC EDGAR.
About Sanara MedTech Inc.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.
Headquarters: Fort Worth, United States · 108 employees · sanaramedtech.com